Geoffrey M. Parker
Presently, Geoffrey M. Parker is Executive VP, Chief Operating & Financial Officer at Tricida, Inc. Mr. Parker is also on the board of ChemoCentryx, Inc., Perrigo Co. Plc, Better Therapeutics LLC and Better Therapeutics, Inc.
Mr. Parker previously was Chief Financial Officer & Senior Vice President for Anacor, Inc., Partner at The Goldman Sachs Group, Inc., Vice President of Feibusch & Co., Inc., Chief Financial Officer & Executive Vice President at Anacor Pharmaceuticals, Inc. and Chief Business Officer of InteKrin Therapeutics, Inc.
He received an undergraduate degree from Dartmouth College and an MBA from Stanford Graduate School of Business.
|05/07/2021||2,786||Derivative/Non-derivative trans. at $42.96 per share.||119,687|
|05/07/2021||5,804||Derivative/Non-derivative trans. at $42.96 per share.||249,339|
|03/17/2021||2,500||Acquisition at $41.29 per share.||103,225|
|05/15/2020||2,906||Derivative/Non-derivative trans. at $52.76 per share.||153,321|
|05/15/2020||6,054||Derivative/Non-derivative trans. at $52.76 per share.||319,409|
|05/15/2019||1,907||Derivative/Non-derivative trans. at $49.55 per share.||94,492|
|05/15/2019||3,971||Derivative/Non-derivative trans. at $49.55 per share.||196,763|
|11/12/2018||3,000||Acquisition at $65.35 per share.||196,050|
|06/06/2018||2,048||Derivative/Non-derivative trans. at $73.22 per share.||149,955|
|06/06/2018||4,265||Derivative/Non-derivative trans. at $73.22 per share.||312,283|
|07/20/2017||246||Derivative/Non-derivative trans. at $75.51 per share.||18,576|
|07/20/2017||511||Derivative/Non-derivative trans. at $75.51 per share.||38,585|
|07/20/2017||690||Derivative/Non-derivative trans. at $75.51 per share.||52,102|
|07/20/2017||1,437||Derivative/Non-derivative trans. at $75.51 per share.||108,507|